Atyr pharma inc (LIFE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Consolidated net income (loss)

-23,763

-34,515

-48,207

-57,855

-

-

-

Net loss

-

-

-

-

-47,973

-24,350

-20,014

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization

635

746

713

900

869

829

714

Issuance of common stock for technology

-

-

-

-

1,411

-

-

Stock-based compensation

1,783

3,431

6,784

5,029

4,856

1,791

155

Debt discount accretion and non-cash interest expense

707

966

590

173

297

-

-

Amortization of debt discount

-

-

-

-

-

426

211

Loss on debt extinguishment

-

-

-

-29

-

-

-

Change in fair value of preferred stock warrant liability

-

-

-

-

-29

-36

28

Accretion of discount of available-for-sale investment securities

284

261

-14

-531

-789

-43

-

Amortization of right-of-use assets

731

-

-

-

-

-

-

Loss on disposal of property and equipment

28

-18

-

-

-

-

-

Deferred rent

-

-

-130

-315

-295

-277

-254

Changes in operating assets and liabilities
Prepaid expenses and other assets

-334

-610

-761

421

666

1,043

-323

Accounts payable and accrued expenses

162

-2,058

-2,889

-932

3,944

-207

1,526

Contract liability

208

-

-

-

-

-

-

Operating lease liability

-498

-

-

-

-

-

-

Net cash provided by (used in) operating activities

-20,013

-31,063

-42,364

-52,861

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-36,797

-22,824

-17,311

Purchases of property and equipment

79

594

1,312

600

664

249

644

Purchases of available-for-sale investment securities

40,647

40,299

77,672

28,089

109,445

5,397

-

Maturities of available-for-sale investment securities

45,600

78,065

51,347

62,216

38,115

3,400

-

Proceeds from sale of property and equipment

51

-

-

-

-

-

-

Net cash provided by (used in) investing activities

4,925

37,172

-27,637

33,527

-

-

-

Cash flows from financing activities:
Proceeds from issuance of common stock through employee stock purchase plan

13

36

175

-

-

-

-

Proceeds from issuance of common stock through option exercises and release of restricted stock units

-

14

186

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-71,994

-2,246

-644

Proceeds from issuance of preferred stock for cash, net of issuance costs

-

-

-

-

75,648

-

38,660

Proceeds from issuance of common stock through initial public offering, net of offering costs

-

-

-

-

76,902

-

-

Costs paid in connection with initial public offering

-

-

-

-

-

999

-

Proceeds from issuance of common stock through option exercises

-

-

-

20

604

72

77

Proceeds from issuance of common stock through at the market offerings, net of offering costs

4,405

379

-

-

-

-

-

Proceeds from issuance of common stock through registered direct offering, net of offering costs

4,918

-

-

-

-

-

-

Proceeds from issuance of securities in the Private Placement, net of issuance costs

-

-

42,477

-

-

-

-

Proceeds from issuance of common stock through employee purchase plan

-

-

-

143

-

-

-

Proceeds from borrowing, net

-

-

9,866

9,736

-

5,000

-

Repayments on borrowings

8,000

4,667

-

5,202

-

-

-

Net cash provided by (used in) financing activities

1,336

-4,238

52,704

4,697

-

-

-

Net change in cash and cash equivalents

-13,752

1,871

-17,297

-

-

-

-

Repayments on loans payable

-

-

-

-

3,237

-

-

Proceeds from notes payable to bank

-

-

-

-

-

-

5,000

Repayments on notes payable to bank

-

-

-

-

-

1,561

2,500

Proceeds from convertible debt

-

-

-

-

-

-

10,000

Repayments of convertible debt

-

-

-

-

2,000

-

500

Net cash provided by financing activities

-

-

-

-

147,917

2,512

50,737

Net change in cash and cash equivalents

-

-

-

-14,637

39,126

-22,558

32,782

Supplemental disclosure of cash flow information:
Interest paid

1,122

1,700

1,000

225

-

-

-

Purchase of fixed assets included in accounts payable

-

4

260

-

-

-

-

Interest paid

-

-

-

-

925

415

254

Supplemental schedule of noncash investing and financing activities:
Issuance of warrants in connection with borrowings

-

-

263

217

-

148

-

Issuance of warrants in connection with long-term debt

-

-

-

-

-

-

137

Changes in share repurchase liability

-

-

48

102

-120

13

-3

Capital contribution related to reversal of historical accretion of redeemable convertible preferred stock

-

-

-

-

-

-

17,528

Conversion of convertible debt and accrued interest

-

-

-

-

-

-

9,537